

Catalent, Inc.  
Form 8-K  
April 29, 2016

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934  
Date of report (Date of earliest event reported): April 28, 2016

---

CATALENT, INC.  
(Exact Name of Registrant as Specified in Charter)

---

Delaware                      001-36587      20-8737688  
(State or Other Jurisdiction   (Commission   (IRS Employer  
of Incorporation)              File Number)   Identification No.)

14 Schoolhouse Road                      8873  
Somerset, New Jersey  
(Address of Principal Executive Offices)   (Zip Code)  
(732) 537-6200  
(Registrant's telephone number, including area code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

“Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

“Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

---

---

Item 8.01 Other Events.

On April 28, 2016, the softgel manufacturing facility of Catalent, Inc. (“Catalent”) located in Beinheim, France received an order from l’Agence National de Sécurité du Médicament et des produits de santé (the “ANSM”), the primary French pharmaceutical regulatory agency, lifting the previously announced suspension of pharmaceutical operations at the site, effective immediately. The order also reiterates Catalent’s commitment to work with its customers to address raw materials and finished products still present from the pre-suspension period in order to manage any risk of possible product contamination.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CATALENT, INC.

Date: April 29, 2016    By:    /s/ STEVEN FASMAN  
Name: Steven Fasman  
Title: Senior Vice President and General Counsel